Phase 1 Colorectal Cancer Trial, Recruiting NCT07349043 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 1 Colorectal Cancer Trial, Recruiting

NCT07349043
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with colorectal cancer that has spread to the lining of the abdomen (peritoneum), confirmed by a tissue test, and has not spread to any other parts of the body
  • People aged 18 to 75 years old (any gender)
  • People whose general physical fitness and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scale called the ECOG score (score of 2 or lower)
  • People who do not have any other type of cancer
  • People who do not have any medical reasons that would prevent them from having laparoscopic (keyhole) surgery
  • People whose doctors estimate they are likely to live for more than 6 months
  • People who are able to understand and sign a consent form agreeing to take part in the trial
  • People whose blood and organ function results meet the following requirements: a sufficient level of infection-fighting white blood cells, platelets, and haemoglobin (noting that a blood transfusion to raise haemoglobin to the required level is acceptable); adequate protein levels in the blood; liver function tests within an acceptable range; and kidney function above a certain level (confirm specific numbers with trial site)

Who may not be able to join:

  • People who have a blockage in their bowel or digestive system
  • People who rely entirely on nutrition delivered through a drip (intravenous feeding) rather than eating
  • People who have uncontrolled fluid build-up in the abdomen (severe ascites)
  • People who have a serious active infection inside the abdomen (peritonitis)
  • People who have extensive internal scarring (adhesions) in the abdomen from previous surgery or illness
  • People who have already had both tumour-removal surgery and bowel reconstruction surgery performed at the same time
  • People who have a blood clot in the portal vein (the large vein supplying the liver)
  • People who have serious or poorly controlled heart conditions, high blood pressure, or active infections (including irregular heartbeat, chest pain, heart failure, or significantly reduced heart pumping function)
  • People who have had a previous allergic reaction to chemotherapy medicines
  • People who have severe heart, lung, liver, kidney, or blood disorders, serious mental illness, or who misuse drugs or alcohol
  • People who are pregnant or breastfeeding
  • People who have taken part in another clinical trial within the past 3 months, or who are currently in another clinical trial
  • People who have a history of neurological or psychiatric conditions (such as severe depression or dementia) that could affect their ability to give informed consent or complete follow-up appointments
  • People who the trial researchers determine are not suitable to participate for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-(571)-8778-3586

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-Limiting Toxicity (DLT); Maximum Tolerated Dose (MTD); Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov